INKT
$9.57
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Recent News
Wall Street Stabilizes After Oil-Driven Volatility as US Equity Futures Waver Pre-Bell
US equity futures were cautiously lower ahead of Tuesday's opening bell as investor sentiment steadi
Agenus (AGEN) Q2 2025 Earnings Call Transcript
My name is Stefanie Nacar, and I'm the Chief Communications Officer here at Agenus. Welcome to our webcast where we'll be discussing topics related to patient care, their experiences, their needs and the work that's required to bring new options to those impacted by cancer, specifically colorectal cancer.
MiNK Therapeutics Inc (INKT) Q3 2025 Earnings Call Highlights: Promising Clinical Results and ...
MiNK Therapeutics Inc (INKT) showcases significant advancements in cell therapy while navigating financial hurdles and planning for future growth.
MiNK Therapeutics (INKT) Earnings Call Transcript
Dr. Jennifer Buell: Thank you, Stephanie. This quarter marks a defining period for MiNK Therapeutics, Inc. We are now a fully independent operated company focused, agile, and singularly dedicated to the advancement of our INKT cell therapy platform. MiNK was founded on a bold idea: that a single naturally derived immune cell type, one of the most highly conserved cells in immunology, the invariant natural killer T cell, a very potent subset of T cells, could be harnessed to both ignite and regulate immunity.
New Strong Sell Stocks for August 22nd
INKT, MNR and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2025.